The tumor cell-autonomous mechanisms include mutations in the EGFR or downstream-related genes [14,15,16], as well as activation of compensatory loops such as human epidermal growth factor receptors 2 and 3 or AXL (HER2 and HER3, respectively) [17,18,19,20]. The gene discussed is EGFR; the disease is neoplasm.